臨床婦人科産科70巻5号

2016年05月発行

今月の臨床 糖尿病が女性ヘルスケア・がんに与えるリスク

糖尿病治療は何が変わったか？

著者： 弘世貴久¹

所属機関： ¹東邦大学内科学講座糖尿病・代謝・内分泌学分野

ページ範囲：P.368 - P.373

文献概要

●糖尿病治療はこの10年余の間にさまざまな進歩を遂げてきた．

●血糖コントロールを厳格に行うことが重要なことは論を俟たないが，低血糖を起こさないことが付帯条件として広く認識されるようになってきた．

●カロリー制限主体の食事療法から栄養素摂取量の調整を念頭においた食事療法が提案されるようになってきたが，結論には至っていない．

●新しい経口糖尿病薬や注射薬の登場が，糖尿病治療の進歩に大きく貢献している．

参考文献

1）The Action to Control Cardiovascular Risk in Diabetes Study Group : Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 : 2545─2559, 2008

2）Johnston SS, et al : Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 34 : 1164─1170, 2011

3）Holman RR, et al : 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 : 1577─1589, 2008

4）Duckworth W, et al : Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 : 129─139, 2009

5）American Diabetes Association : Standard medical care in diabetes -2016. Position Statements, 7. Approaches to glycemic treatment. Diabetes Care 39（suppl 1） : S52─S59, 2016

6）Bazzano LA, et al : Effects of low-carbohydrate and low-fat diets : a randomized trial. Ann Intern Med 161 : 309─318, 2014

7）Johnston BC, et al : Comparison of weight loss among named diet programs in overweight and obese adults : a meta-analysis. JAMA 312 : 923─933, 2014

8）Hall KD, et al : Calorie for calorie, dietary fat restriction results in more body fat loss than carbohydrate restriction in people with obesity. Cell Metab 22 : 427─436, 2015

9）Nauck MA, et al : Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 （7-36 amide） in type 2 （non-insulin- dependent） diabetic patients. Diabetologia 36 : 741─744, 1993

10）Fujimaki KK, et al : Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide. J Diabetes Invest 5 : 400─409, 2014

11）Riddle MC, et al : The treat-to-target trial : randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 : 3080─3086, 2003

12）Heise T, et al : Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 14 : 944─950, 2012

13）Becker RH, et al : New insulin glargine 300U.mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100U.mL-1. Diabetes Care 38 : 637─643, 2015

14）Santer R, et al : Familial renal glucosuria and SGLT2 : from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5 : 133─141, 2010

15）Zinman B, et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 : 2117─2128, 2015

16）Lee Y, et al : Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60 : 391─397, 2011